A Phase I/II Dose-finding Randomized, Single-center, Double-blind, Placebo-controlled Safety and Immunogenicity Trial of the Vesicular Stomatitis Virus-vectored Zaire Ebola Candidate Vaccine BPSC1001 (VSVΔG-ZEBOV) in Healthy Adults.

Trial Profile

A Phase I/II Dose-finding Randomized, Single-center, Double-blind, Placebo-controlled Safety and Immunogenicity Trial of the Vesicular Stomatitis Virus-vectored Zaire Ebola Candidate Vaccine BPSC1001 (VSVΔG-ZEBOV) in Healthy Adults.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Apr 2016

At a glance

  • Drugs RVSV-S-GP/VP40 vaccine (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Most Recent Events

    • 07 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Jan 2016, according to ClinicalTrials.gov record.
    • 07 Dec 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top